Polymer-lipid microencapsulated gases for uses as imaging agents

MYPI1997000890A0Inactive Publication Date: 1998-01-29ACUSPHERE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1997000890
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1996-07-29
Filing Date
1997-03-05
Publication Date
1998-01-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current ultrasound contrast agents for diagnostic imaging have limitations in stability, echogenicity, and duration of action, particularly in aqueous environments like the vascular circulation, leading to suboptimal imaging quality and difficulty in targeting specific body regions.

Method used

Polymer-microencapsulated gases, especially perfluorocarbons, are used within a lipid-based formulation to enhance echogenicity and stability, with specific polymers and lipids like polylactic acid, polyglycolic acid, and phospholipids, which increase the persistence of the contrast agent in the body and allow for targeted delivery.

Benefits of technology

The polymer-microencapsulated gases significantly enhance ultrasound contrast and persistence, enabling improved imaging quality and longer duration of action, particularly in cardiovascular and vascular applications, while minimizing uptake by the reticuloendothelial system.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

IT HAS BEEN DISCOVERED THAT THE INCORPORATION OF GASES, ESPECIALLY FLUORINATED GASES SUCH AS PERFLUOROCARBONS, INTO MICROPARTICLES FORMED FROM THE COMBINATION OF A NATURAL OR SYNTHETIC POLYMER AND LIPID HAVE SIGNIFICANTLY ENHANCED ECHOGENICITY AS COMPARED WITH MICROPARTICLES NOT INCLUDING THE LIPID. COMPOUNDS OTHER THAN LIPIDS WHICH ARE HYDROPHOBIC AND LIMIT THE PENETRATION AND / OR UPTAKE OF WATER INTO THE MICROPARTICLES CAN ALSO BE INCORPORATED INTO THE MICROPARTICLES TO ENHANCE ECHOGENICITY. IN THE PREFERRED EMBODIMENT,THE POLYMERS ARE SYNTHETIC BIODEGRADABLE POLYMERS. THE MICROPARTICLES ARE MANUFACTURED WITH A DIAMETER SUITABLE FOR THE TARGETED TISSUE TO BE IMAGED, FOR EXAMPLE, WITH A DIAMETER OF BETWEEN 0.5 AND 8 MICRONS FOR INTRAVASCULAR ADMINISTRATION, AND A DIAMETER OF BETWEEN 0.5 AND 5 MM FOR ORAL ADMINISTRATION FOR IMAGING OF THE GASTROINTESTINAL TRACT OR OTHER LUMENS. PREFERRED POLYMERS ARE POLYHYDROXY ACIDS SUCH AS POLYLACTIC ACID-CO-GLYCOLIC ACID, MOST PREFERABLY CONJUGATED TO POLYETHYLENE GLYCOL OR OTHER MATERIALS INHIBITING UPTAKE BY THE RETICULOENDOTHELIAL SYSTEM (RES). THE MOST PREFERRED LIPIDS ARE PHOSPHOLIPIDS, PREFERABLY DIPALMITOYLPHOSPHATIDYLCHOLINE(DPPC), DISTREAROYLPHOSPHATIDYLCHOLINE (DSPC), DIARACHIDOYLPHOSPHATIDYLCHOLINE (DAPC), DIBEHENOYLPHOSPHATIDYLCHOLINE (DBPC), DITRICOSANOYLPHOSPHATIDYLCHOLINE, DILIGNOCEROYLPHATIDYLCHOLINE (DLPC), INCORPORATED AT A RATIO OF BETWEEN 0.01-30 (W LIPID / W POLYMER), MOST PREFERABLY BETWEEN 0.1-10 (W LIPID / W POLYMER). MICROPARTICLES FOR IMAGING USING OTHER DETECTABLE AGENTS CAN BE SIMILARLY MANUFACTURED.
Need to check novelty before this filing date? Find Prior Art

Description

POLYMER- MICROENCAPSULATED GASES FOR USE AS IMAGING AGENTSBeckground of the InventionTbe present invention is generally the area of diagnostic imaging agents, and Is particularly directed to micraparticiriafit ultrasound mging contrast agents laving lipid incorporated therein to maintain the Khogeoicity over time.When using ultrasound 10 obtain an image of the organs tri structures of a human or anim, ultrasound waves, waves of sound tnergy at a. frequency above that discernable by the human ear, are reflected as they pass through the body. Different types of body tissue reflect the ultrasound waves differently and die reflections that Vt produced by the ultrasound waves reflecting off difEsicnt internal itnicbues axe detected and converted electronically into a visual display.For some medical Cooditiansf obtaining a useful image of the organ or structure of interest is especially difficult because the details of the structure are not adequately discernible from the surrounding tistue in an ultrasound image produced by the reflection of ultrasound waves absent a contrast-enhancing agent Detecdaa and observation of Otttain physiology and pathological conditions may be substantial improved by enhancing the contrast in an ultrasound image by infiismg an agent into an organ or other scruourc or InsyesL In other cases, detection of themovement of the contrast-enhancing agent itself is particularly important For example a distinct blood flow pattern that is known to remit from particular cardiovascular abnormalities may only be discernible by infusing a contrasting agent into the bloodstream and observing the dynamks of the blood flow.MatariaU that ate useftl as ultrasound contrast agents opemc by having an effect on ultrasound waves as they pass through the body and are reflected to create the image from which a medical is toad.Diffeitmt types of substances affect ultrasound waves in diflbstt ways and to varying degrees. Moreover, certain of the effects caused by contrast shwing agents arc more readily measured and observed thsri others. In selecting an ideal composition for a comrast handng agent, one would prefer the substance that has the moat dramatic effect on the ultrasound wave as it passed through the body, Aiaop the effect on the ultrasound wave should be easily measured, there are throe main comrast-ecinDcmg effects which can be seen in an ultrasound image: backwater, beam attenuation, and speed of sound difca.BACKSCA U fcR: When an ultrasound wave that is passing through the body encounters a structure, such as an organ or other body tissue, the structure reflects a portion of the ultrasound wave. Dlflbam structures within the body reflect ultrasound energy in dffiuwt ways and in varying strengths. This reflected energy is detected and used to generate an image of the stnitboes through which the ultrasound wave has passtil The term "bacfcscatter* tefei to the phenomena in which ultrasound energy is scattered bade towards Ae source by a substance with certain physical properties.It has long been recognized that the contrast observed in an ultrasound image may be enhanced fay the presence of substances known 1 to cause a large amount of backscatzer When such a substance is admimsteted to a distinct part of the body, the contrast between the ultrasound image of this part of the body and the surrounding tissues not comaining the substance is enhanced. It is weU understood that, doe to their physical properties, different substances came hadac*ter in varying degrees. Accordingly, the search for coptrast-qihancfng agents has focused on substances that are stable and non-toxic and that exhibit the maximum nu amount of backscatter.The capability of a substance to cause backscatter of ultrasound energy depends on characteristics of the substance such as its ability to be compressed. When examining different substances, it is useful to ctnnpare one particular measure of the ability of a substance to cause backscatter known as the "scattering cross-section. The scattering crosssection of a particular substance is proportional to the radius of the scatxerer, and also depends on the wavelength of the ultrasound energy and on other physical properties of the substance, J. Ophir and K.J. Parker, Contrast Agatts in Diagnostic Ulinuouitdt Ultrasound in Medicine & Biologyv vol. IS, n. 4, p. 319, 323 (1989).In evaluating the utility of different substances as image contrasting agents, one can calculate which agents should have the higher scattering cross-section and, accordingly, which agents should provide the greatest contrast in an ultrasound image. It can be assumed that the compressibility of a solid particle is much less than that of the surrounding medium aad that the density of the particle is much greater. Using this assumption, the scattering cross section of a nUd particle contrast-enhancing agent has been esdmated as 1.75 (Ophir and Parker, supra, at 325). For a pure liquid scanner, die adkbatlc Cvmyi^sftulity and density of the scaoerer and the surrounding medium ate likely to be approximately equal» which would yield the result that liquids would have a scattering crosfr-section of zeco. However, liquids may exhibit some < badocausr if large volumes of a liquid agent are pimat. For example, if a liquid agent passes from a very small vessel to a very large one such that the liquid occupies substantially all of the vessel, the liquid may exhibit measurable baclncattet. Neverthelesil it is appreciated by those skilled in the art that pure liquids are relatively inefficient tcaeterei? compared to free gas microbubbles.BEAM ATTENUATION:Another effect which can be observed from the presence of certain solid contrast-enhancing agents, is the attenuation of the ultrasound wave. Imnge contrast has been obeerved in conventional imaging due to localized auEouation difference* between certain tissue types. KJ. Packer and R.C. Waxtgl "Measurement of Ultrasonic Attenuation Within Regions selected from B-Scan !magea." IEEE Trtmst BiometL Enar. BME 30(8), p. 431-37 (1983); KJ. Paifel R-O. Wasgl and SLM. Leraer, " Atteei«dan of Ultrasound Μ·^^ and Frequency Dcpendsre for Tiaaue Characterization," Badktagy, 153(3), p. 785-88 (1984). It has been hypothesized that measurements of the attenuation of a region of tissue taken before and after in&aion of an agent may yield an enfinOTri image. However, tnchniqun baaed on azceimition contrast as a means to measure the contrast snbm^ment of a liquid agent are not well-developed andv even if ftilly developed, may suffer from limitations as to the internal organs or structures with which this technique can be used. For Czample1 it is imliksJy that a Iosa of attenuation due to liquid contrast agents could be observed in the image of the cardiovascular system because of the high volume of liquid contrast agent that would need to be present in a given vessel before a Sub^awrt*1 diffcrencfe in aeemmiion could be measured.Absorption of energy by the particles occurs by a mef*ni«™ referred to as "relative motion." The change in attenuation caused by relative motion can be shown to increase UnsrIy with particle concccmtion and as the square of the density diffcteooe between the particles and the surrounding medium. K.J. Paiker1 et al., "A Partkailate Contrast Agosft with Potential for Uhrasound LaiagiDg of liver / , Ultrasound in Medicine ά Siolcgyt Vol. 13, No. 9, p. 555, 561 (19S7). I Therefore, where substantial accumulation of solid particles occurs, attenuation, contrast may be a viable mccb»"tfm for observing image contrast cohancsnjesr although the cffect is of much smaHer magnfmrin than the backacaoer phenomenon and would appear to be of litda use in cardiovascular diagnoses.SPHED OF SOUND DIFFERENTIAL: An additional technique to eihance contrast in an ultrasound image has been proposed based on the fact that the speed of sound varies depending on the media through which it travels. Therefore, if a huge enough volume of an agent,through which the speed of sound is different than the surrounding tissue.can be infiiaed into a target area, the difference in the spaed of Bound through the target area may be measurable.In summary, dlagnoatic ultrasound is a powerful, non-invasive tool that fTtn be used to obtain information on the «gfcgfml nynt of the body.The advent of grey scale m**giag and color Doppler have greatly advanced the scope and resolution of the technique. Alihrugh tirbniquiM for carrying out diagnostic ultrasound have improved significantly, and for making and using contrast agents, then is still a need to enhance the resolution of the imaging for cardiac perfusion and cardiac chambers, solid organs, renal perfusion; solid organ perfusion; and Doppler signals of blood velocity and flow directkm during real-time lmaftng.A variety of natural and synthetic polymers have been usod to encapsulate imaging contrast agents, such as air. Schncidor et ai, Invest, Rfldiol.. Vol. 27, pp. 134-13$ (1992) describes three mkrca, air-filled polymeric particles. These panicles were reported to be stable in plasms and under applied pressure. However, at 2.5 MHz1 their echogenicity was low. Another type of microbubblc suspension has been obtained from sonicated albumin. Feinstein et atJ- Am Con. CmiioL. Vol. Ht pp. 59-65 (1988)» Feinsiiem describes the preparation of microbubbles that are appropriately siasd for transpulmcmary passage with err^lW stability in vitro. However, these microbubbles are short-lived in vrvo, having a half life on the order of a few seconds (which is apprfissnattly equal to one circulation pass) because of their instability under pressure. Gottlieb, S. et aL, I. Am. Soc. Echo.. Vol. 3. pp. 328 (1990), Abstract; and Shapiro, IA. et al., J. Am. Coll. Cardiol.. Vol. 16, pp. 1*03-1607 (1990). pelatin-encgpEuUcted air bubbles have been described by Carroll etal. (Carroll, B.A. etal.t Invest· Radiol.. Vol. 15, pp. 260-266 (1980), and Carroll, B.A. tt al.. Radiology. Vol. 143, pp. 747-750 (1982)), bat due to their large sizes (12 and 80 jim) they would not be likely co pis through pulmonary capQliiries. Gelatin-encapsuiaied microbubbles have also been described in PCT / US80 / Q0502 by Rasor Associates. Inc. Thne are formed by "coalescing" the gelatin.Micxobubbles stabilized by microcrysUls of galactose (SHU 454 and SHU 508) have also been reported by Fritzch et al. Fritach, T. et Cl, Tfw*t Pacini Vol. 23 (Suppl 1), pp. 302-305 (1988); and Fritzsch. T. et al., Tnwtf PaHinI Vol. 25 (Suppl 1), 160-161 (1990). The microbubbles last up to IS in vitro but lets than 20 seconds in vivo Rovai, D. tt at.. J Am. Call. Catdlol.. Vol. 10, pp. 123-134 (1987); MKl Smith, M. a aL, J. Am. Coll. CMdioI.. Vol. 13, pp. 1622-1628 (1989). Gu microbubbles encapsulated within a shell of a fluorine-contaimrig material l* described in WO 96 / 04018 by Mcriecular Bioaystem Inc.EBnjpean Pateat Application No. 90901933.5 by Scberiog AJoiengetelUcbafi disclose* the preparation and use of microencapsulated gas or volatile liquids for ultrasound imagine, when the microcapsules are formed of syrahetic polymers ffl polysaccharides. European Patett Application No. 91810366.4 by Smtetiea S.A. (0 4S8 743 Al) disdom . air or gas mkroballoons bounded by an interfseuBy deposited polymer membrane that can bo dispersed ift an aqucoos canter for Injection into a hoe aahsaJ or for oral, rectal, or urethral Sdzmniarttionl for therapeutic or diagnostic purposes. WO 92 / 18164 by Delta Biotechnology T.tmiipd describes the preparation of micrDpankks by spray drying under very controlled conditions as to temperature, rats of ipiaying, particle sire, and drying conditions, of an aqueous protein solution to fcna hollow spheres laving gas entrapped therein, for use in imaging. WO 93 / 25242 describes the synthesis of micropirtides for ultrasonic ""aFnIT consisting of a gas cosbiised within a shell of polycyaooacrylate or polyester. WO 92 / 21382 discloses the fabrication of micropartkle contrast agents which include a eovalently bowled matrix caaaitang a gas, wherein the tutrix is a carbohydrate. U.S. PateS Nos. 3434.381. S, 123,414 and 5,332,433 to Unger describe liposomes for use as ultrasound contrast (gents, which inctude gases, gas precursors, soch as a pH activated or photo-activated gaseous precursor, as well as other liquid or solid contrast enhancing agents.U.S. Patent No. 3.393,324 to Quay discloses the use of agents, including fluorocarbons, for HihEwHng the contrast in an ultrasound image. The agents consist of extremely " bubbles, or microbubblaa, of selected gases, which ech&ii long life spans hi solution and ar saaS enough to traverse the hags, enabling their use in ultrasound imaging of the cardiovascular system and other vital organs. WO 95 / 23613 by Nycomed discloses microcapsules Ibr tnnjwg which are fanned by coacervation of a solution, far Ciampk, a protein solution, conaming * perfUiorocarbon. PCT / US94 / 0841G by MauachusetQ Imtime of Technology discloses microparticles formed of polyethykne glycol· poly(lactide-co-glycolide) blodc polymers having imaging item encapsulated therein, iv.tuding gases such u air and perfluorocaibons. As described in WO 94 / 16739 by Sonut Pfcaepssastieals, Inc., while »alids and liquids ieflect sound to a iimiUr degree, gases'are known to be more efficient and are the pre&ned media for use as nHr»«nnnd contrast agents. In fact, as shown by ewagrie 12 of the Sonus FCT application, protein microcapsules were ^iftIW* a* raising safety conocrns (u wall as «fiicacy issues) when administeMd to mini-pigs, as compared Co THiLrions or colloidal suspensions.None of these describe micrapartieles which can be detected using other methods for detection, such as x-ray, position or photon emission tomography, or magnetic resonance imaging.In all of these cases it is desirable to enhance the echogenicity of the imaging aJ***. in conjunction with enhancing or "fi""·»»^ tfac stability and ease of mtiffl^eturing of die imaging agst*. One way in whUh to increase the echogenicity of a micropaiticle is η increase the time encapsulated gase* remain in the cireilaiiag micrqpyticlc*. UnfortunatEty, in most cases, lbs gases difltae out rapidly, regardless of the TwfUTE of die gas or tbe encapsulating material, particularly in the aqueous environment of the vascular circulation.It is therefore ω object of the presets invention to provide mlcroparticles with significantly enhanced echogenicity. It is another object of the invention to provide mlcroparticles containing an ****?E*"g agent that can persist for more than a few dieuletinn thnes tx vivo. It is a Anther object of the present Inventian to provide aiizOparticlss wbkh retain encapsulated gas for longer periods of time, therefore inaeaasg the in Wvo echogenicity of the ttucroparticles.It-is mother object of the invents·™ to provide mtroparticles Whkb WW'· an imaging agent. It is a farther object of the invention to provide microparticles containing imaging agcsts, that are targeted to specific regions of the body. It is still another object of the present invention to provide methods for making microparticles having imaging agents entrapped therein.Summary of the InventionIt has been discovered that the incorporation of gases, especially fhiornated gases such as perfhiorocarbons, into microparticles lbmied from the combination of a cawal or synthetic polymer and lipid hive «jgnifig«nriy <mh«i«rt echogenicity as compared with microparticle· not inehytiig the lipid. Confounds other than lipids wMch are hydrophobic and limit the diftkision of water into the microparticles can also be incorporated into the micrepgrticles to enhance echogenicity. In the pre fated embodiment, the polymers are synthetic biodegradable polymers. The microparticles are manufactured with a suitable for the targeted tissue to be imaged, for example, with a ^"-nrtgr of between 0.5 and 8 microns for intravascular adniffliitatian, and ι aimieter of between 0.5 and 5 mm for oral administration for BTtttTnI of the gastrointestinal tract or other lumens. Preferred polymers are polyhydroxy acids such as polylactic acid-eo-glycolic acid, polylactide or polyglycolide, most preferably conjugued to polyethylene glycol or other materials inhibiting uptake by the reticuloendothelial system (RES). The most preferred lipids are phospholipids, preferably dipalmitoy!phosphatidylcholine (DPPC), disteatoy !phosphatidylcholine (DSPC), diarachidoylphosphagdylctoline <DAPC). dibehenoylphosphstirfylcholine (DBPC). dltricosanoylpfaosphttyylcholisB (DTPC). dilignoceroylphatidy choline (DLPC), incorporated at a ratio ofbetween dOl-30 (w lipid / w polymer), most preferably between 0.1-10 (w lipid / w polymer).Adhesion of these mlcroparticles can be enhant^ or reduced through the selection of bioadhesive polymers. For example, adhesion can be «nhanrrri in the case where the polymer is used for oral administration. Targeting can also be achieved by setoeddb of die polymer or incorporation within or coupUog to die polymer of ligands which specifically bind to particular tissue types or cell surfacc molecules. Additionally. ligand« may be attached to the microspheres which effect the charge, lipophilicity or hydrophilicity of die particle. The polymeric microparticles are useful in a variety of diagnostic imaging procedures including ultrasound anaging, magnetic resonance imaging, fluoroscopy, x-ray, and computerized tomography. The microspheres may be uaed in a variety of imaging applications including cardiology applications, blood I, perfusion applications as well as for organ and peripheral vein imaging.Brief Description of the DrawingFigure 1 is a graph of the effect of carbon eham length of lipid incorporated into polymeric mkropactlcles, plotted as de$ee of beckscatcering over time (minute?) for lecithin (solid circles), DPPC (open squares), PSPC (open diamonds), and DAPC (X).Detailed Description of the InventionMethods are provided for the synthesis of polymeric delivery systems consisting of polymer-lipid microparticles which contain gases, especially pearfluorocacbons. The micropartteles are useful m a variety of diagnostic ultrasound imaging applications, particularly m ultrasound prooeduses such as blood vessel Imaging and echocardiography. The incorporation of lipid significantly increases the echogisdciiy as compared with die same polymeria mscmpaiticlee without the additional lipid.Processes and Reagents for Making MicroparticlesAs used herein, the term mieroparticle includes microspheres and microcapsules, as well as microparticles, unless otherwise specified. Micropanicki may or may not De spherical in shape. Mtetocapsufei are defined as mkiopamcles having an outer polymer shell surrounding a core of another material, in this case, a gas. Microspheres are generally solid polymeric spheres, which can include a haoeyoombod structure formed by pores through the polymer which are filled with a gas for imaging purposes, as described below.PolymersBoth non-biodegradable and biodegradable matrices can be used mixed widi lipids for delivery of gates, although biodegradable matrices are preferred, particularly for inoaveneus injection. Non-erodible polymers may be used for oral administration. Synthetic polymers are preferred due to moie reproducible synthesis and degradation. The polymer is selected based on the time required for in vtvo stability, i.e., that time required for distribution to the site whete imaging is desired, and the time required for imaging. In one embodiment, mterytrtictes with an In vtvo stability of between about 20 to 30 Tniwrtes or more may be fabricated, for example for use in applications such as echocardiography, neurosonography, hysterosalpingography, and diagnostic procedures on solid organs. The in vivo stability of Ibe contrast agent-encapsulated mkroparticlee can be adjusted during the production by using polymers such as polylactide co glyoolide copoiymerized with polyethylene glycol (PEG). PEG if exposed on the external-surface may elongate the time these materials ctrculais since it is hydrophilic.Representative synthetic polymers are: polyChydroxy adds) such as poly (lactic acid), poly(glycollc acid), and polrflactic aratao-glycolk acid), polyglycolidea, polylactidcs. potylactide co-glycolide copolymers and blends, polyanhydrldes, polyocthoecten. polyamides; polycarbonates, polyalkylenes such as polyethylene and polypropylene, poly alkylene glycols such, as poly (ethylene glycol), polyalkylene oxides such as poly(echylene oxide), polyalkylene taepdulates such as poty(ethylene teicphtfuiaie), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halidcs such as poly(vinyl chloride), polyvinylpyrrolidone, polysiloxanes, poty(viny1 alcohols), polyvinyl acetate), polystyrene, polyurethanes and co-polymers thereof, derivittvned celluloses such as alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, methyl cellulose, ethyl ccUulose, hydroxypropyl ocllulose, hydroxy-propyl methyl cellulose, hydioxybutyl methyl oellulose, cellulose acetate, cellulose propionate, cellulose acetate hutyratci'cellulose acetate phchalate, carboxylethyl cellulose, cellulose txiacctate, and cellulose sulphate sodium salt (jointly referred to hetein as "synthetic celluloses")» polymers of acrylic acid, methaccylic acid or copolymers or derivatives thereof inrinrfing esters, poiy(mctfayl methacrylate), poly(ethyl methacrylate), poly (butylmcthacryUte), poly(isobutyl methacrylate), poly(bexylmethacrylate), poly(isodecyl methacry laic), po\y(lanryl methacrylate), poly(phenyl methacrylate), poly(methyl aery late), poly(isopropyl acrylate), poly(isoburyl aery late), and poly(octadecyl aery late) Qointly referred to herein as "polyacrylic acids"), poly(butyric acid), poly(va!eric acid), and poly<lactide-co-caprolactone), copolymers and blends thereof. As used herein, "derivatives" include polymers having substitutions, actions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other mpdifications routinely made by those skilled in the ait.Examples of preferred non-biodegradable polymer* include ethylene vinyl acetatc, poly(xaeth)aciylic acid, polyamidec, copolymers and mixtures thereof.Examples of preferred biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid, polyiictide, polyglycoUde, polylactide-co-glycoUde, and copolymers with PBG; polyanhydridu, poly(ortho)ertcr», polyurethicfis, poly (butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), blends and copolymers thereof.Examples of preferred natural polymers include proteins such as albumin and prolamines, for example, zein, and polysaccharides such as alginate, cellulose and polyfaydroxyaliranoates, for example* polytydroxybutyiate.Bioadhesive polymers of particular interest for use in imaging of mucosal surfaces, as in the gastrointestinal tract, intinde polyanhydrldes, polyacryUc acid, poLy(methyl methacrylates), po)y(ethyl mcthacrylates), poly(buty Imcthacrylate), polyfisobucyl methacrylate), poly (hexylmetbaciylate), polyOsodecyl metfeeciylate), polyClauzyl metbacrylate), poly(phenyl methacrylate), poly(methyl acrylaie), poly(isopropyl acrylaie), poly(isobutyl aery late), and poly(octadecyl acrylaie).SolventsAs defined herein, the polymer solvent is an organic solvent Otat is volatile or has a relatively low boiling point or can be removed under vacuum and which is acceptable for administration to m traceamounts, snch as methylene chloride. Other βOlvnnts1 such as ethyl acetate, ethanol, methanol, dimethyl fbrmamide (DMF), acetone, acctonitrik, fietrahydrofluan (THF), acetic acid, dhnethyle sulfoxide (DMSO) and chloroform also may be utilized, or combinations thereof. In general, the polymer is dissolved in the solvent to fbzxn a polymer solution having a concentration of between 0.1 and 60% weight eo volume (w / v), more preferably between 0.25 and 30%.Hydrophobk Compounds LipidsIn general, incorporation of compound? which are hydrophobic and, in an effective amount, thereby limit penetration and / or uptake of water by Ae micropaxticles are effective in mcy«*ng echogenicity of polymeric mkroparttclcs having gas encapsulated themn, especially fluorinated gaaes such as perfluorocaibont. Lipids which may bo sand tostabilize gas inside the polymeric microparticlcs include but are not ifrpitP^i to the following classes of lipids: Atty adds and derivatives, mono-, di and triglycerides, phospholipids, sphiqgolipids, dnlestenjl and steroid derivatives, terpcncs and vitamins. Fatty acids and derivatives thereof may include but are not limited to «atnraied ami unsaturated fatty acids, odd and even number fatty acids, cis and trans isomers, and fatty acid derivatives including alcohols, ester», anhydrides, hydroxy Catty acids and prostaglandins. Saturated and unsaturated fatty acids that may be used include, but are not limited to, molecules that have between 12 carbon atoms and 22 carbon atoms in either linear or branched form. Examples of saturated fatty acids that may be used include, but are limited to, laurici myrisdc, palmitic, and stearic acids. Esiamples of unsaturated fatty acids that may be used include, but are not limited to, Uuricl pbySfiieric1 myristoleic, pahsitolezc, petrosdinic, and oleic acids. Examples of branched ffcny acids that may be used mdiide, but are not limited to. isolauric, isomyristic, lsopahsltlc, and isoseearic acid» and isoptewrids. Fatty acid derivatives include 12-4X0'-diethyiBmisocoumarinr3 yl)carbonyl)methylamino)-octadecanoic acid; N-[12(((7'diethytammocoumarin-3-yl) carbonyl)methyl-amino) Octadecayl)-2-aminopalmitic acid, N succinyt-dioleoylphospbatidylethanol amine and palmltoyl-homocysteiDe; and / or combinations thereof. Mono, di and triglycerides or derivatives thereof that may be used include, but are not IjmitBd to molecules that have fatty acids or mixtures of fatty acids between 6 and 24 carbon atoftu, digalactosyldiglyceride, l,2^oleoyI<m-glycecoL;l,2-<dipafaniMyl-sn-3 succinylglyccrol; and l,3~dipalmimyl-2-cuccinylglyoerol.Phospholipids which may be used include but are not limiasd to phosphatide acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl edunolamines, phosphatidylglycerols, phosphatidylserines, phosphatidyllnositols, lysophosphatldyl derivatives, cardiolipin, and ß-acyl-y-alkyl phospholipids. Eautmptea of phospholipids include, but are not Ihalted to, phosphatidylcholines such as dioleoy !phosphatidylcholine, dimyristoylphosphatidylcholme, dipcntadecanoylphosphatidylchoUnc dilauroylphosphatidylcholiiie, dipilmitoylphosphatidylcholiiic (PFPC)1 distcajoylphospbaridylcholiiiB (DSPC)t diarachidoy lptophylcboline (DAPC)1 dibehencylphosphaiidylcholine (DBPC)1 ditricosalphosphafidylcholinc (DTPC), diijgnoceroylphatidylcholii* CDLPO; and phosphatidylediMWlauOoaes such as dioleoylphosphaor 1-hcxadecyl-2-palmitcylglycerophoephoetiianola^ Syofiietic phospholipids with asymmetric acyl chains (e.g., with one acyl dab of 6 , carbons and another acyl chain of 12 carbons) may also be used.Sphingolipids which may be usod include ceramides, sphmgomyetins, ccrebrosides, gangliosides, sulfetides and lysosulftiides. Samples of SpMngiolipids include, but are not limited to, the gangliosides GMl and GM2.Steroids which may be used include bur are not limited to cholesterol, cholesterol sulfate, cholesterol hemisucdnate, 6-(5-cholesterol 30-yloxy) hexyl-6-amino-6-deoxy-6-thio-a-D-galactopyranoside 6-(5- cholesten-3 ^-tloxy)hexylamiiKJ-6Kieoxyl-1-thio-a^D manoopyianoeide and cholestery 1)41 -tnsethyl 35 ammonio)butanoate»Additional lipid compound which may be used include tocopherol and derivatives, and oils and derivadzed oils such as etearbrtmhie.A variety of cationic lipids such as DOTMA, N-[1-(2,3-(lioleoylony)PropyUN1 N, N-trtmethyUmmonium chloride;* DOTAP1 1,2-dioleoyloxy-3-(trimed2ylaminonio) propane; and DOTS, 1,2-dioleoyl-3-(4' -trimethyl- amino) bmanoyl^sn glycerol may be used.The most preferred lipids an phospholipids, preferably DPPC, DDSPCt DAPCf DSPC» DTPC, DBPC. DLPC and most preferably DPPC, DAPC and DBPC.The lipid content ranges fcsa .01-30 (w lipid / w polymer); SlDflt preferably between 0.1-10 (w lipid / w polymer).Otiur BjdrOphotic CompoundsOther preferred hydrophobic compounds include amino acids such u tryptophane, tyrosine. Isolcucine, lnidne, and valine, aromatic confounds such aa as alky) paiaben, for example, methyl pnaben, and benzoic acid.Imaging Agttits GasesAqy biocompatible or pharmacologically acceptable gas can be incorporated into the microparticles. The term gas refers to any compound which is a gas or capable of forming a gas at the temperature at which imaging is being poformed. Tbe gas may be qmumsed of a single compound such as oxygen, Aftzogen1 xenon, argon, nitrogen or a mixture of compounds such as air. Fluorinatedd gases are preferred. Examples of fhiorinatod gases include CF4, C1Fs, C3Fat CJF1. SF9v CtFf, and C3Ffi. Peifhioropropane Is ρUtkulariy preferred because it provides an insoluble gas that will not co^f^e at the tempsaturo of use and is pharmacologically acceptable.Other Imaging AgentsOther frMg^g agents can be incorporated in place of a gas, or in combination with the gas. Imaging agents which may be utilinid include commercially available ageooi used m positron emission tomography (PET)1 computer assisted tomography (CAT), single photon emittkra computerized tomography, x-ray, fluoroscopy, and magnetic eeemaaeai imaging (MRI). Micropaniclci loaded with these agents can be detected using standard available in the art and commercially available equipment.Examples of suitable materials for use as Goatzast ageaa m MRI Include the gatalimum chelates currently available, mh as dietfcylcae triamine pentacedc add (DTPA) and gatopentotasa dattegtamfo aa well as iron, magnesium, manganese, copper and chromium.Examples of msaerials weful for CAT aid x-rays include ksdme baaed materials for taavenous administrtion such as ionic nwoncwn typified by djatrizoate and iothalamate, non-ionic monomer? such as iopamidol, isobexol, and iovcrsol, non-ionic dimen, such as iotrol and iodixanol, and ionic dimers. for example, ioxagaltc. Other useflti materials include barium for oral use.Micropartxks and Methods for Manufacture Thereof In the most preferred embodiment, the microparticles are produced by spray drying. Other techniques can be used, such as solvent extraction, hot melt encapsulation, and solvent evaporation, as dimmed below. A major criteria is that the polymer must be dissolved or melted with the lipid, prior to forming the raicroparticle. Although described specifically with reference to incorporation of a lipid, it is understood that other useful hydrophobic compounds could be substituted for the lipid,In a preferred embodiment, the gas is then replaced by applying a stream of the desired gas το, or pulling a vacuum on, the microparticles to remove the encapsulated gas, than filling with the desired gas.a. Solvent Evaporation. In this method the polymer and lipid are dissolved In a volatile organic solvent such as methylene chloride. A port forming agent as a solid or in solution may be added to the solution, for use in forming microparticles which are to incorporate gas as the imaging agent. If other imaging agents are to be Incorporated, the imaging agent can be added as either a solid or in solution to the polymer solution. The mixture is sonicated or homogenized and the resulting dispersion or emulsion is added to an aqueous solution that con&ins a surface active agent such as TWEEN™ 20, TWEEN™ 60, PEG or poly<vinyI alcohol) and homogenised to form an *muls?on. The resulting emulsion is stirred until most of the organic solvent evaporates, leaving microparticles. Several different polymer concentrations can be used (0.05-0*60 gftnl). Microparticks with different sizes (MOOO microns) and morphologies can be obtained by this method. This method is useful for relatively stable polymers like polyesters.Solvent evaporation i* described by E. Matfaiowta> et al.. L Seinftirf Mlcraicqnv. 4, 329 (1990); L.R. Bedc, Ctll-. PcrtiL St^L. 31, 545 (1975); and S, Benitaf et alM J Phtm Sd.. 73, 1721 (1984).However, labile polymers, such aa polyanhydrides, may degnde during the fabrication process due to the presence of water. For these polymers, the following two methods, which axe performed in completely organic solvents, are more useful.b. Hot Melt Microencapsulation. In this method, the polymer and lipid are Inrsi melted and then mixed with the solid particles of the pore forming agent or solid or liquid diagnostic agent. The mixture is suspended in a ncn-miscible solvent (like silicon oil), and, while stirring eaotiaaqusly, heated to 5*C above the melting paint of the polymer. Onoe che amission if stabilized, it U cooled mQ die polymer particle* solidify. The resulting micxopanickj are wasted by docantation wish a polymer non-solvent such as petroleum ether to give a free-flowing powder. Micropartkles with sires between one to 1000 microns can be obtained with this method. The external surfaces of particles prepared with this technique are usually smooth and dense. This procedure is used to prepare micropenis!** made of polyesters and polyanhydrides. However, this method is Undted to polymers with rwrtl^lIar weigh* between 1000-50,000.Hot-melt mlcToeucapeiladon la described by E. MaSskmitz. et al.. Reactive Polymers. 6, 275 (1987). Polyanhydrides, foe example, made of bis-caiboxyphenoxypropaae and sebacic acid with molar ratio of 20:80 (P(CPP-SA) 20:80) (Mw 20,000). can be prepared by hot-melt microencapsulation or for ezan^le» pofy(fUxnaric-co-sebecic) (20:80) (Mw 15,000) mieroparticles, can be prepared by hot-melt microencapsulation.c. gfdv»m Hamoval. This technique was primarily designed for polyanhydrides. In this method, the poie forming agent is or dissolved in a solution of (he selected polymer and Upki In a volatffo organic solvent like methyleoc chlorite. Thia mixture ia suspedsd by stifTing in an organic oil (such as silicon oil) to form an emulsion.Unlike solvent evaporation, this method can be used to mzkm microparticles from polymers with high melting points and differs molecular weights. Tbe external morphology of panicles produced with this Eecimigue is highly dependent on the type of polymer used.d. Snrav Drviny gf Microparticles Mfcropaiticlee Can be produced by spray drying by dissolving a biocompatible polymer and lipid in an appropriate solvent, disponing a pore forming agent Into the polymer solution, and then spray drying the polymer solution· to form microparticles. As defused herein, the process of "ipcay drying" a I solution £f a polymer and a pore forming agent refers to a process wherein the solution is atomized to form a fine mis; and dried by direct cosdact with hot carrier gases. Using spray drying apparatus available in the art, the polymer solution may be delivered through the inlet pan of Ibe spray drier, passed through a tube within the drier and then ntnmliBd through the outlet port. The temperature may be varied depending on the gas or polymer used. The temperature of the inlet and outlet ports can be controlled to product the d^sed products.The size of the particulates of polymer solution is a function of the nozzle used to spray the polymer solution, nozzle pressure, the flow rate, the polymer used, the polymer cocceotraUoa, the type of solvent and the temperature of spraying (both inlet and outlet temperature) and the molecular weight. Generally, the higher fte molecular wvigbi, the larger the particle size, assuming the concentration is the same. Typical process parameters for spray drying are as follows: polymer concentration * 0.005-0.20 g / ml, inlet temperature 30-10004C, outlet temperature * 20-IOOeCy polymer flow rate — 5-2Q0 ml / min. and nozzle dimeter ™ 0.2-4 mm JD. Mkropanicles ranging in diimeter between one and ten microns can be obtained with a morphology wbich depends on the selection of polymer, concentration, molecular weight and spray flow.If the imaging agent is a solid, the agent may be encapsulated u solid particles which are added to the polymer solution prior to spraying, or the imaging agent can be dissolved in an aqueous solution which thai 25 emulsified with the polymer solution prior to spraying, or die solid may be cosohibilizcd together with the polymer m an appropriate solvent prior to spraying.e. Hvdrogel Microparticles. Microparticles made of gel-type polymers such as polyphosphazene or polymethylmethacrylate, are produced by dissolving the polymer in an aqueous solution, suspeskUng if desired a pore forming agent and suspending a lipid in the mixture, homogenizing the mixture, and extruding the material through a microdroplet forming device, producing mkrodroplcts which fill into a HafrWtmg bath consisting of an oppositely charged ion or potyelectrolyte solution, that is slowly stimd. The advantage of these systems is the ability to fhrther modify the surface of the nucropattidei by coating them with polycationic polymers, like polylysiae after ftbric»rt"iL Microparticle particles are controlled by using various size extruders.Additives to Facilitate Microparticulate FormationA variety of surfactants may be added during the synthesis of the image agent-containing mlcroparticles. Exemplary emulsifcn or surfactants which may be used (0.1-5% by weight) includr most physiologically acceptable emylsifiets. Examples include natural and synthetic forms of bile salts or bile adds, both conjugated with amino acids and unconjugated such as taurodeonycholate. and cholic acid.Pore forming agents can be included in an amount of between 0.01% and 90% weight to volume, to increase pore formation. For «temple, in spray drying, solvent evaporation, a pore forming agent such as a volatile salt, for example, ammonium, bicarbonate, acetate, ammonium chloride or ammonium bcngoate or other lyophilizable salt, is first dissolved in water. The solution containing the pore forming agent is then emulsified with the polymer solution to create droplets of the pore forming agent in the polymer. This emulsion, is then spiaj dried or taken through a solvent evaporation / extraction process. After the polymer is precipitated, the hardened microparticles are frozen and lyophflised to remove the pore forming agents.Microparticle SizeIn a preferred embodiment for the preparation of Injectable micitjparticles capable of passing through the pulmonary capillary bed, the microparticks should have a diameter of between approximately one and tea microns. Larger microparticles may clog the pulmonary bed. and smaller igictoparticles may not provide sufficient echogenicity. Larger I microparticles are useful for administration by routes other than Injaezfrin1 for example oral (for evaluation of Oic gastrointestinal tract), application to other mucosal surfaces (rectal, vaginal, oral, nasal) or by irfoisHon The preferred particle size for oral admsastration is about 0.S microns and 5 mm. Usefol pharmaceutical^ acceptable carriers include "line confining glycerol and TWEENtm 20 and isotonic maimhol containing TWEEN™ 20. Particle size analysis can be performed on a Coulter counter by light microscopy, seamdng election microecopy, or transmiitance electron microscopy.TargetingThe microparticles can be targeted specifically or nofrspocxficatiy through die selection of (he polymer forming the micro particle, the size of the micropaiticle, and / or incorporation or of a ligand to the micropahicies. For example, biologically active molecules, or molecules affecting the charge, lipophiikity or hydrophilicity of the particle, may be attached to Oie surface of the micropanicle. Additionally molecules may be attached to the microparticles which minimize tissue adhesion, or which facilitate specific targeting cf the mkmpartides in vivo. Representative targeting molecules include anybodies, lectins, and other molecules which are specifically bound by receptors on the surfaces of cells of a particular type.inhibition of Uptske by the EESUptake and removal of the microparticles can also be "minimize through the selection of the polymer and / or incorporation or coupling of molecules which adhesion or uptake. For example, tissue adhesion by the microparticle can be minfrnir*rf by covaleutly binding poly(allQrlene glycol) moieties to the surface of (he mktopvticle. The surface poly(aIkylene glycol) moieties have a high affinity for water that reduces protein adsorption onto the surface of the particle. The recognition and uptake of the mjcropaxticlc by the teticulo-endothelial systm (RES) is therefore reduoed.For example, the terminal hydroxyl group of the poly(alkylene glycol) can be used to covalwaly attach biologically active molecules, or molecules affecting the charge, lipophiliciiy or hydrophiliesfy of the particle, onto the surface of the microparticle. Methods available in the art can be used to attach any of a wide range of llgands to the microparticles Co die delivery properties, the stability or other properties of the microparticles « vivo.Diagnostic ApplicationMicroparticles are typically combined with a phamaceutically acceptable carrier such as phosphate buffeted saline or saline or mannkol, then an effective ainmirrt for detection administered to a patient using an appropriate route, typically by irtfcction into a blood vessel (i.v.) or orally. 'Micioparticles containing an encapsulated imaging agent may be used in vascular imaging, as well as in applications to detect Iivw and renal diseases, m cardiology applications, in ^y^ng and chanctoriziEg tumor masses and dssues, and in measuring peripheral blood velocity. The microparticle* also can be linked with Uganda that wrinimw· tissue adhesion or that target the miaopaxticles to specific regions of the body in vivo aa described above.The methods and coiqpoaitione described above will be fcrfter understood with reference to the following non-limiting examples.Example 1; Preparatiou of Octnflnnropropene PEG-PLGA / PLGA microp articles with Lecithin.3.2 gnmis of PEG-PLOA (75:25) (IV-0.75 dUg Bicsimgfcam Polymers), 6.4 g FLGA (50:50) (IV* A dUg Meoley Chemicals). 23mg Lecithin (Spectrum Chemicals), and 193 mg of Palmitic Acid CSpectnmi Chemicals) ware dissolved in 190 tal of Mkyleae chloride. 10.1 ml ofOJO g / ml irnmonium aeetate was added to the polymer solution and the 1 polymer / ..ammonium acetate was added to the polymer solution and the polymer / ammonium acetate mixture was homogenised at 10,000 RPM for 1 minute using a Virtis homogeniser. The solution was pumped at a flowraie of 20 ml / min and sprayed dried using a Bucchi Lab spray dryer. The inlet temperature was 40 ο C. The microparticle powder was collected and lyophiliied on an FTS tray IyophjHaer for 120 hours. Tfae mietopanJcles were aliquoted into 5 ml Purfonn vials and sealed with butyl stoppers and crimped. The vials were filled with octofluoropropane at a pressure of 10 pslg and purged continuously under the gas for three minutes. After this point the vials were stored at 4 ο C until used. The particle diameters ranged from 1-10 microns when sized on a coulter counter with a number average mean of 2.0 microns. Scanning electron microscopy demonstrated the particles to be generally spherical with smooth surfaces and occasional surface crnmilaimns. Esaznple 2: Preparation of Octafluoropropane PEG-PLGA / FLGA micropartkles with dipahaitoylphocphatidykholme (DPPC).Micropartides were prepared aa in Example 1 except 29.6 mg of dipalmitoytphosphatldylcboline (Avanti4 Birmsgham Al) was used in place of the lecithin.Example 3: Preparation of Octaftuoropropane PEG-PLG A / FLGA micropartkles with distearoylphnaphatidylchofiee (DSPC).Microparticles were prepared as in Example 2 except that 29.9 mg of distearoylphosphaiidylcholine (Avanti, Birmingham Al) was used in place of the lecithinExample 4: Freparatioa of Octafluoropropane FEG-FLGA / FLGA microparticles with diarachtdeytphosphafeidylcfaftltoe (DAPC).Microparticles were spared as in Example 2 except that 29.9 mg of diarachidoylphosphaddylcholine (Avanti, Birmingham Al) in place of the lecithin.EssmpW 5: In Vitro Measurement of Micropartide Backscatter.The backscatter of the different octafluoropropane containing polymeric microparticles produced in Exanqiles 1-4 was obtained by exposing 10 microliters of suspension of die microparticles to a focused ultrasound beam. The backacattered acoustic power as a fraction of depth into the sample was rfrfr^rninM u follows. A pulser-iecertier OPanametricse Model 5800) was used to shock excite a focused ultrasound transducer (2.25 MHz), which sends a pulse of ultrasound into the suspension of microparticles in physiological saline.The suasion was confined in & cylindrical sample rfwwber (55 ml of saline) which is situated in a tempefaftue-conttulled watet bath adjusted to 37* C. The chamber was positioned 1.5 inches from the transducer, such that die transducer was focused on the acoustic window of die chamber. Chambers were rotated at 15 rpm to ™fa*MSn the microparticles in suspension. The dissolved gas conteitf of the saline was maintained at approximately 90% of air saturation, as by a dissolved oxygen meter (Orion* model 840). The operation of the acoustic test system is controlled by a PC running a proprietary program written under Lab VIEW· (National Instruments9). The computer triggered the pulser-ieceiver to shock excise the ultrasound transducer.The baekscattned signal was received by the same transducer. ud die returned signal was amplified by Ihe pulser*eceivar unit. The amplified signal was passed to a digital oscilloscope (LeCroy model 9310AM) for digitization at 100 MSa / s. The digitised signal was further processed, The signal was squared, analyzed by FFT and integrated ow die 6 dB bandwidth of the transducer. The acoustic data collected by diesystem was converted to Uuesrated bactacattered power (IBP)1 m arbitrary xmlN, as a Ainction of depth in the ntfcroparticulate suspension. Tbe IBP vs depth date from 50 pulses were averaged, the test-fitting Anight line through the averaged IBP data determined and the y-intercept which is proportional to the backscatter coefficient was determined. Bacft sanple was tested at 2.5 minute intervals over a total time period of 10minutes.The backscatter as a function of time for the four different mkroparticle lots is shown in Figure 1. Lecithin is a mixture of different chain length phospholipids. As the chain length of the fatty acid attached to the phosphocholine is increased, the of backscatter is more sustained over a longer period of time indicating increased stability of die octafhioropropane in the microparticles. Using the highly purified phospholipids is also more effective at stabilisation of the gas as compared to the mixture of phospholipids contained in lecithin.

Claims

We claim:

1. Ά method for making microparticles for diagnostic imaging, wherein the microparticles are formed of a bio-compatible polymer and have incorporated therein gas, the improvement comprising (a) incorporating into the polymer a hydrophobic compound by either dissolving the polymer and hydrophobic compound in an organic solvent or melting the polymer with the hydrophobic compound, prior to forming the microparaticles, and (b) forming the microparticles by either removing the polymer solvent or cooling the polymer, wherein the hydrophobic compound is mixed with the polymer in the micropartlcle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound and wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids , prostaglandins , phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid.2 . The method of claim 1 wherein the hydrophobic compound is incorporated with the polymer at a ratio of between 0.01 and 30 by weight of hydrophobic compound to weight of polymer.3 . The method of claim 2 wherein the hydrophobic compound is a lipid incorporated with the polymer at a ratio of between 0.01 and 30 (weight lipid / weight polymer) .4 . The method of claim 1 wherein the lipid is a phospholipid selected from the group consisting of phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl ethanolamines , phosphat idylglycerols, phosphatidylserines, phosphatidyl inositols, lysophosphatidyl derivatives, cardiolipm, and β-acyl-yalkyl phospholipids .

5. The method of claim 4, wherein the phospholipid is selected from the group consisting of dioleoylphosphatidylcholine , dimyri stoy1phosphat idyl choline, dipentadecanoylphosphat idvlcholine, dilauroylphosphatidylcholine, dipalmi toylphosphat idyl chol ine , distearoylphosphat idylchol ine , diarachidoylphosphat idylchol ine , d ibehenoylphosphat idylchol ine , ditricosanoylphosphatidylcholine, dilignoceroylphat idylcholine; and phosphat idylethanolamines.

6. The method of claim 1 wherein the gas is selected from the group consisting of fluorinated gases, oxygen, xenon, argon, helium, and air.

7. The method of claim 6 wherein the gas is selected from the group consisting of CF„, C2F6, C3Fa, C,Fe, C«F10, SF6, C;F<, and C3F6.

8. The method of claim 7 wherein the gas is octafluoro-propane.

9. The method of claim 1 wherein the microparticle is formed of a synthetic polymer.

10. The method of claim 1 wherein the microparticle is formed of a natural polymer.

11. The method of claim 1 wherein the microparticle is formed of a bioadhesive polymer.12 . The method of claim 9 wherein the microparticle is formed of a synthetic polymer selected from the group consisting of poly(hydroxy acids), polyanhydrides, polyorthoesters , polyamides , polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides , polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcohols), polyivinyl acetate), polystyrene, polyurethanes and co-polymers thereof, synthetic celluloses, polyacrylic acids, poly(butyric acid), poly (valeric acid), and poly(lactide-co-caprolactone), ethylene vinyl acetate, copolymers and blends thereof.

13. A composition for diagnostic imaging comprising biocompat ible polymeric microparticles incorporat ing a gas which are formed by the steps of (a) dissolving the polymer and a hydrophobic compound in an organic solvent or melting the polymer and the hydrophobic compound, prior to forming the microparticles, (b) forming the microparticles by removing the solvent or cooling the polymer, wherein the hydrophobic compound is mixed with the polymer in the micropart icle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound, and wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids , prostaglandins, phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes, tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid.

14. The microparticles of claim 13 wherein the hydrophobic compound is incorporated with the polymer at a ratio of between 0.01 and 30 by weight of hydrophobic compound to weight of polymer.

15. The microparticles of claim 14 wherein the hydrophobic compound is a lipid incorporated with the polymer at a ratio of between 0.01 and 30 (weight lipid / weight polymer).

16. The micropart icles of claim 13 wherein the lipid is a phosphol ip id selected from the group consisting of phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl ethanolamines , p h o s p h a t i d y 1 g 1 y c e r ο 1 s , p h o s p h a t i d y 1 s e r i n e s , phosphatidylinositols, lysophosphatidyl derivatives, cardiolipin, and β-acyl-yalkyl phospholipids.

17. The microparticles of claim 16 wherein the phospholipid is selected from the group consisting of dioleoylphosphatidylcholine , dimyristoylphosphat idylcholine, dipentadecanoylphosphat idylcholine diiauroylphosphatidylcholine , dipalmitoylphosphatidylchol i ne , distearoylphosphatidylcholine, diarachidoylphosphatidylchol ine , dibehenoylphosphat idylchol ine , ditricosanoylphosphatidylcholine, dilignoceroylphatidylcholine -, and phosphatidylethanolamines .

18. The microparticles of claim 13 wherein the gas is selected from the group consisting of fluorinated gases, oxygen, xenon, argon, helium, and air.

19. The microparticles of claim 18 wherein the gas is selected from the group consisting of CF4, C;F6, C,Fe, C4FE, C,F.o, SF6, C2F4, and C3F6.

20. The microparticles of claim 19 wherein che gas is octafluoropropane .

21. the microparticles of claim 13 wherein the microparticle is formed of a synthetic polymer.

22. The microparticles of claim 21 wherein the polymer is selected from the group consisting of poly(hydroxy acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyaikylene thereof, synthetic poly(butyric acid), glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcholols), poly(vinyl acetate), polystyrene, polyurethanes and co-polymers celluloses, polyacrylic acids, poly(valeric acid), and poly (lactide-co-caprolactone), ethylene vinyl acetate, copolymers and blends thereof.

23. The micropart icles of claim 15 wherein the lipid is liquified with the polymer to form the microparticles .24 . The microparticles of claim 23 wherein the lipid and the polymer are dissolved in a solvent for both, then formed into microparticles.2 5. The micropart icles of claim 23 wherein the gas is incorporated into the microparticle after the polymer and lipid have solidified.

26. The microparticles of claim 13 where the polymer is a natural polymer selected from the group consisting of proteins and polysaccharides.

27. In a method for increasing the hydrophobicity of microparticles formed of a biocompatible hydrophobic polymer and having incorporated therein a gaseous imaging agent, the improvement comprising dissolving the polymer and a hydrophobic compound in an organic solvent or melting the polymer and a hydrophobic compound, removing the solvent or cooling the polymer to form the microparticles, wherein the hydrophobic compound i s mixed with the polymer in the microparticle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound .

28. The method of claim 27, wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids, prostaglandins, phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes, tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid .